The pattern and severity of side effects in long-term users of two common hormonal therapies for breast cancer, anastrozole and tamoxifen, may be related to age, according to a new analysis from researchers at the University of California, Los Angeles Jonsson Comprehensive Cancer Center’s Cancer Prevention and Control Research program.
The study examined data from 1,193 patients enrolled in a Phase III clinical trial, in which the two drugs were compared in postmenopausal women with